Akari Therapeutics

NASDAQ: AKTX · Real-Time Price · USD
0.99
0.02 (2.05%)
At close: Aug 15, 2025, 3:24 PM

Akari Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 4K 3.71K 4.13K
Gross Profit
n/a -4K -3.71K -4.13K
Operating Income
-21.64M -16.81M -23.09M -17.21M
Interest Income
8K 82K 45.94K 10.6K
Pretax Income
-19.79M -10.01M -17.75M -17.42M
Net Income
-19.79M -10.01M -6.97M -17.61M
Selling & General & Admin
9.66M 11.36M 13.53M 8.08M
Research & Development
6.98M 12.13M 9.56M 9.13M
Other Expenses
5M -6.68M 802.79K -27.48K
Operating Expenses
21.64M 16.81M 23.89M 17.21M
Interest Expense
-244K n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 16.81M 23.09M 17.21M
Income Tax Expense
n/a n/a -10.78M 182.62K
Shares Outstanding (Basic)
11.94K 4.89K 3.12K 2.15K
Shares Outstanding (Diluted)
11.94K 4.89K 3.12K 2.15K
EPS (Basic)
-160 -200 -220 -820
EPS (Diluted)
-160 -200 -220 -820
EBITDA
-21.64M -16.8M -23.08M -17.21M
EBIT
-20.04M -16.81M -23.09M -17.21M
Depreciation & Amortization
-1.61M 4K 3.71K 4.13K